Zhong Guo Zheng Quan Bao·2026-02-28 01:42Core Viewpoint - Rongchang Biopharma (688331) reported a significant increase in revenue and profitability for the year 2025, indicating a strong turnaround and growth potential in its core products and strategic partnerships [2][4]. Financial Performance - The company achieved an operating revenue of 3.251 billion yuan, representing a year-on-year growth of 89.36% [2]. - The net profit attributable to shareholders was 709 million yuan, marking a turnaround from a loss in the previous year [2]. - The non-deductible net profit was 65.06 million yuan, compared to a loss in the same period last year [2]. - Basic earnings per share were 1.29 yuan, with a weighted average return on equity of 24.88%, an increase of 78.95 percentage points from the previous year [7]. Valuation Metrics - As of the close on February 27, the company's price-to-earnings (P/E) ratio (TTM) was approximately 78.61, the price-to-book (P/B) ratio (LF) was about 23.85, and the price-to-sales (P/S) ratio (TTM) was around 25 [2]. Growth Drivers - The core products, Taitasip and Vedisitomab, saw rapid growth in domestic sales, becoming the main drivers of the company's performance [4]. - The company secured a significant partnership with Vor Biopharma Inc., granting exclusive global development and commercialization rights for Taitasip outside Greater China, leading to a substantial increase in technology licensing revenue [4]. - Management optimization and production process improvements contributed to reduced unit production costs and increased gross margins, alongside a notable decrease in sales expense ratios [4].